Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03545113 · ClinicalTrials.gov registry record · NA
Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT03545113 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 44 participants.
The verdict
NCT03545113, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
Many older adults require hemodialysis for advanced chronic kidney disease, but it is not clear which permanent vascular access method (fistula or graft) is best with respect to access effectiveness and patient satisfaction. In this pilot study, the study team will test the hypothesis that older adults undergoing graft access placement will more effectively transition from catheter-based to arteriovenous access-based hemodialysis; have fewer following vascular access procedures; have better upper extremity function; have better self-sufficiency with daily activities; and better health-related quality of life compared to those who undergo arteriovenous fistula access placement. The study will establish feasibility of randomizing older adults to the two types of arteriovenous access surgeries; evaluate relationships between measurements of pre-operative physical function and vascular access development; compare vascular access outcomes between the two groups; and gather longitudinal assessments of upper extremity muscle strength, performance of activities of daily living, and patients' reports of satisfaction with their vascular access and quality of life.
Interventions
- PROCEDURE Upper arm arteriovenous graft surgery
- PROCEDURE Upper arm arteriovenous fistula surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-09-04 |
| Est. Completion | 2021-02-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03545113
The ClinicalTrials.gov registry entry for NCT03545113 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Upper arm arteriovenous graft surgery is the first listed.
NCT03545113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03545113 about?
NCT03545113 is a clinical study titled "Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease". Many older adults require hemodialysis for advanced chronic kidney disease, but it is not clear which permanent vascular access method (fistula or graft) is best with respect to access effectiveness and patient satisfaction. In this pilot study, the study team will test the hypothesis that older adu...
What is the current status of trial NCT03545113?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2018-09-04. Estimated completion is 2021-02-22.
What interventions are being tested in trial NCT03545113?
The interventions under investigation include: Upper arm arteriovenous graft surgery (PROCEDURE), Upper arm arteriovenous fistula surgery (PROCEDURE).
Who is sponsoring clinical trial NCT03545113?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.